Isatuximab Carfilzomib Lenalidomide Dexamethasone

Phase 3Small molecule

Isatuximab Carfilzomib Lenalidomide Dexamethasone is one of 25 small molecule programs targeting Multiple Myeloma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Multiple MyelomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Isatuximab Carfilzomib Lenalidomide Dexamethasone

EEuropean Myeloma Network B.V.

Phase 3

1 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 3Active, not recruiting

Multiple Myeloma

NCT04483739

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

Active, not recruiting·EEuropean Myeloma Network B.V.·Phase 3·NCT04483739·302 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Isatuximab Carfilzomib Lenalidomide Dexamethasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isatuximab Carfilzomib Lenalidomide Dexamethasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isatuximab Carfilzomib Lenalidomide Dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — European Myeloma Network B.V. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEuropean Myeloma Network B.V.

Isatuximab Carfilzomib Lenalidomide Dexamethasone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News